Page 2 - Roy Fleischmann News Today

Trial data pave way for FDA approval

But is Russian backing a problem for U.S. approval?

Rheumatologists debate whether problems in the implementation of a treat-to-target approach in patients with RA stem from the metrics used to define targets or rheumatologists efforts to use them.

Rates of patients stopping disease-modifying antirheumatic drugs (DMARDs) have begun to rise after initially falling during the pandemic, with consequent rises in the incidence of disease flares.

Successful implantation and treatment underway in world's first patient receiving experimental therapy for Rheumatoid Arthritis (RA) using splenic nerve stimulation Electrical stimulation